Hearing loss stands as the most prevalent sensory deficit among humans, posing a
significant global health challenge. Projections indicate that by 2050, approximately 10% of …

Gene therapies for hearing loss are expected to enter clinical trials in the immediate future.
To provide referral for appropriate trials and counseling regarding benefits of genetic …

Adeno-associated viral (AAV) vectors are increasingly used as vehicles for gene delivery to
treat hearing loss. However, lack of specificity of the transgene expression may lead to …

Tmc1 and Tmc2 are essential pore-forming subunits of mechanosensory transduction
channels localized to the tips of stereovilli in auditory and vestibular hair cells of the inner …

Abstract Gene Therapy Medicinal Products consist of a recombinant nucleic acid intended
for the modulation or manipulation of a genetic sequence. A single administration of a novel …

Over the past decade, in vivo gene replacement therapy has significantly advanced,
resulting in market approval of numerous therapeutics predominantly relying on adeno …

Nowadays, vaccines are broadly used to prevent porcine circovirus type 2 (PCV2) infection-
induced expenditures, but the virus is still spreading among pigs. The current PCV2 …

Sensorineural hearing loss is typically caused by damage to the cochlear hair cells (HCs)
due to external stimuli or because of one's genetic factors and the inability to convert sound …

Hearing loss (HL) can be caused by a number of different genetic factors. Non-syndromic HL
refers that HL occurs as an isolated symptom in an individual, whereas syndromic HL refers …

Usher syndrome (USH) is the leading cause of combined deafness and blindness, with
USH2A being the most prevalent form. The mechanisms responsible for this debilitating …